GENE ONLINE|News &
XORTX Therapeutics Integrates Renal Anti-Fibrotic Program from Vectus Biosystems into Kidney Disease Portfolio
XORTX Therapeutics Inc. has announced an update regarding its acquisition of a renal anti-fibrotic therapeutic program from Vectus Biosystems Limited. The company confirmed that it is progressing with the integration of this program into its portfolio, which focuses on therapies for progressive kidney disease and other related health conditions.
The acquisition involves a therapeutic program aimed at addressing fibrosis in the kidneys, a condition linked to chronic kidney disease and organ failure. XORTX stated that this addition aligns with its mission to develop innovative treatments for patients suffering from kidney-related illnesses. The company continues to work on advancing the acquired program through preclinical and clinical development stages while ensuring compliance with regulatory requirements. Further updates on the progress of this initiative are expected as development milestones are achieved.
Newsflash | Powered by GeneOnline AI
Source: GO-AI-ne1
For any suggestion and feedback, please contact us.
Date: February 4, 2026
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
LATEST
Amrize Corporation Appoints Three New Directors Following Departure of James Carter and Linda Nguyen
2026-02-11
Study Maps Cellular and Molecular Changes in Pancreatic Tissue During Type 1 Diabetes Progression
2026-02-11
Applied Materials Resolves U.S. Export Control Investigation with Financial Penalty and Compliance Measures
2026-02-11
